
China Structural Reform Fund appeared to be the VC, which was created in 2016.
When the investment is from China Structural Reform Fund the average startup value is more than 1 billion dollars. The usual things for fund are deals in the range of more than 100 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The important activity for fund was in 2018.
Among the most popular portfolio startups of the fund, we may highlight JD Logistics, WM Motor, Ouyeel. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as E-Commerce, Autonomous Vehicles.
The usual cause for the fund is to invest in rounds with 5 partakers. Despite the China Structural Reform Fund, startups are often financed by Tencent Holdings, Shougang Fund, Shagang Group. The meaningful sponsors for the fund in investment in the same round are Tencent Holdings, Sequoia Capital China, Sequoia Capital. In the next rounds fund is usually obtained by Taihang Industrial Fund, Linear Venture, Baidu.
Related Funds
Fund Name | Location |
Affirma Capital | England, London, United Kingdom |
B & C Holdings | Austria, Vienna |
East West Bank | California, Pasadena, United States |
Enzyme Venture Capital | Argentina, Buenos Aires, Distrito Federal |
FAN Communications | Japan, Tokyo |
iResearch | Beijing, Beijing, China |
Keiyo Gas | Chiba Prefecture, Ichikawa, Japan |
Kern Whelan Capital | California, San Francisco, United States |
VAS Ventures | Community of Madrid, Madrid, Spain |
Wadhwani Foundation | Bengaluru, India, Karnataka |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Immorna | $13M | 27 Feb 2023 | Hangzhou, Zhejiang, China | ||
Xiaodu Tech | 19 Jan 2023 | - | |||
COFCO Fortune | $3B | 17 Jan 2023 | Beijing, Beijing, China | ||
GAC Aion New Energy Automobile | $2B | 21 Oct 2022 | Guangzhou, Guangdong, China | ||
Cygnus Biosciences | $30M | 05 Aug 2022 | Changping District, Beijing, China | ||
Xuelangyun | $46M | 16 May 2022 | Wuxi City, Jiangsu, China | ||
Tianxinhe Biotech | 11 Mar 2022 | Wujiang, Jiangsu, China | |||
MetaX | $154M | 24 Aug 2021 | Shanghai, China | ||
TransThera Biosciences | $100M | 25 Jul 2021 | Nanjing, Jiangsu, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.